ClinicalTrials.gg
Not yet recruitingNCT07950670Updated Nov 20, 2026

Laparoscopic Ultrasound-Guided Removal of Multiple Uterine Fibroids

An interventional study of Laparoscopic Ultrasound-Guided Myomectomy and Conventional Laparoscopic Myomectomy in Uterine Fibroids (Leiomyoma), sponsored by Hua Li. Not yet recruiting at 1 site in China. Open to female participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Hua Li · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Leiomyoma with a site in China — 20 open to participants now, 23 under way, 2 of them phase 3. Leiomyoma · China.

Planned enrollment
17th of 29
110 · median 120
Started
2026
with 4 others
No phase
15 of 40
9 open now
Primary completion
2029-01
later than 22 of 22 live
Registered
40th of 40
by date

Among the 40 studies in Leiomyoma with a site in China, this one is the 17th largest by planned enrollment of the 29 interventional ones that give a count, is one of 5 that started in 2026, is one of 15 with no phase, reaches primary completion later than 22 of the 22 other live ones, and was the 40th registered.

Leiomyoma

439 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.

Browse Leiomyoma studies →

Open to participants now

20 of the 40 studies in Leiomyoma with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 44 Leiomyoma studies recruiting now, 23 (52%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 20 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Leiomyoma with a site in China, or all of them as a file.
02

Study summary

This study will examine whether ultrasound guidance during laparoscopic surgery can help surgeons remove uterine fibroids more completely. Uterine fibroids are noncancerous growths in the womb (uterus). Small fibroids or those deep in the uterine wall may be difficult to identify during surgery. Laparoscopic ultrasound uses a probe inside the abdomen to provide images of the uterus during the operation.

The study plans to enroll 110 premenopausal women aged 20 to 50 who have multiple uterine fibroids, need surgery, and wish to keep their uterus. Participants will be assigned by chance to laparoscopic ultrasound-guided myomectomy or conventional laparoscopic myomectomy, with 55 participants planned for each group. Myomectomy is surgery to remove fibroids while preserving the uterus.

The main outcome is the percentage of fibroids removed. For each participant, this is calculated by dividing the number of fibroids removed during surgery by the total number removed plus the number remaining on postoperative imaging, and multiplying by 100. Remaining fibroids will be assessed by transvaginal ultrasound or pelvic magnetic resonance imaging within 3 months after surgery.

Researchers will also assess the percentage of participants with remaining fibroids at 3 months, the difference between the number of fibroids removed and the number identified before surgery, surgical safety, postoperative recovery, and questionnaire scores related to sexual function, disability, anxiety, and quality of recovery. Follow-up visits are scheduled at 1, 3, and 12 months after surgery.

Read the detailed description

Preoperative magnetic resonance imaging will be used to assess and count uterine fibroids. During laparoscopic ultrasound-guided myomectomy, the ultrasound probe will be placed in direct contact with the uterus to help locate fibroids and guide their removal. This approach is intended to improve identification of small or deep fibroids that may not be apparent on visual inspection. In both study groups, decisions about fibroid removal will be individualized, with clinical benefit and safety as the priorities.

Allocation will use stratified block randomization based on age, fibroid number, and maximum fibroid diameter, with a block size of four. A statistician who is not involved in recruitment or clinical intervention will generate the randomization sequence. Group assignments will be kept in sequentially numbered, sealed, opaque envelopes and revealed after completion of the baseline assessment and confirmation of enrollment.

Surgeons will be aware of treatment allocation. Outcome assessors and data analysts will remain blinded to group assignment.

03

Conditions studied

  • Uterine Fibroids (Leiomyoma)

Browse trials for

Keywords

  • Laparoscopic Ultrasound
  • Laparoscopic Myomectomy
  • Multiple Uterine Fibroids
  • Residual Fibroids
  • Intraoperative Ultrasound
04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptomatic multiple uterine fibroids causing symptoms such as abnormal uterine bleeding, anemia, or pressure symptoms, with an indication for laparoscopic myomectomy and a desire to preserve the uterus.
  • Diagnosis established through clinical evaluation, preoperative transvaginal ultrasound, and magnetic resonance imaging (MRI), with MRI used for the final assessment and fibroid count.
  • Age 20 to 50 years and premenopausal, with or without future fertility plans.
  • No to laparoscopic surgery.

Exclusion criteria

Exclusion Criteria:

  • Concomitant submucosal fibroids classified as FIGO types 0-2.
  • Findings suspicious for on preoperative assessment.
  • Uterine size equivalent to 20 weeks of gestation or greater; a history of pelvic inflammatory disease; severe endometriosis; grade III or IV uterine prolapse; or a history of intestinal obstruction, recurrent pelvic inflammatory disease, pelvic tuberculosis, or surgery for pelvic or abdominal tumors.
  • Known severe hepatic or renal dysfunction.
  • Known hematological disorders, bleeding or coagulation disorders, active bleeding at any site, or a bleeding tendency.
  • Severe central nervous system, cardiovascular, hepatic, renal, gastrointestinal, respiratory, endocrine or metabolic, musculoskeletal, or psychiatric disorders. Endocrine or metabolic disorders include thyroid disease, Cushing's syndrome, and hyperprolactinemia.
  • Acute infection.
  • Inability to sign the form.
  • Known or suspected poor adherence that would prevent completion of the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Laparoscopic Ultrasound-Guided Myomectomy

    Participants will undergo laparoscopic myomectomy with intraoperative laparoscopic ultrasound guidance to locate uterine fibroids and assist their removal.

    Procedure: Laparoscopic Ultrasound-Guided Myomectomy

  • Active comparator
    Conventional Laparoscopic Myomectomy

    Participants will undergo conventional laparoscopic myomectomy without intraoperative laparoscopic ultrasound guidance.

    Procedure: Conventional Laparoscopic Myomectomy

Interventions

  • ProcedureLaparoscopic Ultrasound-Guided Myomectomy

    During laparoscopic myomectomy, a laparoscopic ultrasound probe will be placed in direct contact with the uterus to identify and localize fibroids and guide their removal. Fibroid removal will be individualized according to clinical benefit and safety.

  • ProcedureConventional Laparoscopic Myomectomy

    Uterine fibroids will be removed using conventional laparoscopic myomectomy without intraoperative laparoscopic ultrasound guidance. Fibroid removal will be individualized according to clinical benefit and safety.

06

What researchers measure

Primary outcomes

  1. Fibroid Removal Rate

    For each participant, the fibroid removal rate is calculated as the number of fibroids removed during surgery divided by the sum of the number removed during surgery and the number of residual fibroids detected by postoperative transvaginal ultrasonography or pelvic magnetic resonance imaging, multiplied by 100.

    Time frame: During surgery and within 3 months after surgery

Secondary outcomes

  1. Residual Uterine Fibroid Rate

    Percentage of participants with at least one residual uterine fibroid detected by transvaginal ultrasonography or pelvic magnetic resonance imaging at the 3-month postoperative visit. The rate is calculated as the number of participants with residual fibroids divided by the total number who underwent surgery in each group, multiplied by 100.

    Time frame: 3 months after surgery (+/- 14 days)

  2. Difference Between Removed and Preoperatively Identified Fibroid Counts

    For each participant, the difference is calculated as the number of fibroids removed during surgery minus the number identified on preoperative magnetic resonance imaging.

    Time frame: Preoperative assessment and during surgery

  3. Operative Time

    Duration of the surgical procedure, measured in minutes.

    Time frame: During surgery

  4. Estimated Intraoperative Blood Loss

    Estimated volume of blood lost during surgery, measured in milliliters.

    Time frame: During surgery

  5. Participants With Intraoperative Complications

    Number of participants experiencing at least one intraoperative complication, including hematoma, ureteral injury, or neurovascular injury.

    Time frame: During surgery

  6. Participants With Postoperative Complications

    Number of participants experiencing at least one postoperative complication, assessed during postoperative hospitalization and at scheduled follow-up visits.

    Time frame: From completion of surgery through 12 months after surgery (final visit window: +/- 14 days)

  7. Postoperative Length of Hospital Stay

    Time from completion of surgery to hospital discharge, measured in days.

    Time frame: Perioperative

  8. Postoperative Pain Score

    Postoperative pain intensity assessed using a visual analog scale at 2 and 6 hours after surgery. Higher scores indicate more severe pain.

    Time frame: 2 and 6 hours after surgery

  9. Time to First Postoperative Ambulation

    Time from completion of surgery to first postoperative ambulation, measured in hours.

    Time frame: Perioperative

  10. Time to First Postoperative Flatus

    Time from completion of surgery to first passage of flatus, measured in hours.

    Time frame: Perioperative

  11. Duration of Postoperative Uterotonic Treatment

    Duration of postoperative uterotonic medication use, measured in hours.

    Time frame: Perioperative

  12. Time to Postoperative Drain Removal

    Time from completion of surgery to removal of the surgical drain, measured in hours, among participants with a drain placed.

    Time frame: Perioperative

  13. Participants With Postoperative Urinary Dysfunction

    Number of participants with postoperative urinary dysfunction, assessed at each scheduled follow-up visit.

    Time frame: 1, 3, and 12 months after surgery (each visit window: +/- 14 days)

  14. Participants With Postoperative Bowel Dysfunction

    Number of participants with postoperative bowel dysfunction, assessed at each scheduled follow-up visit.

    Time frame: 1, 3, and 12 months after surgery (each visit window: +/- 14 days)

  15. Change From Baseline in Female Sexual Function Index Score

    Change from the preoperative baseline in the total Female Sexual Function Index score at each postoperative assessment. The questionnaire assesses sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. Higher scores indicate better sexual function.

    Time frame: Baseline (before surgery), 3 months, and 12 months after surgery (postoperative visit windows: +/- 14 days)

  16. Change From Baseline in Oswestry Disability Index Score

    Change from the preoperative baseline in the Oswestry Disability Index score at each postoperative assessment. The questionnaire assesses disability associated with lower back or leg pain. Higher scores indicate greater disability.

    Time frame: Baseline (before surgery), 1, 3, and 12 months after surgery (postoperative visit windows: +/- 14 days)

  17. Change From Baseline in Zung Self-Rating Anxiety Scale Score

    Change from the preoperative baseline in the Zung Self-Rating Anxiety Scale score at each postoperative assessment. The questionnaire contains 20 items assessing anxiety symptoms. Higher scores indicate more severe anxiety.

    Time frame: Baseline (before surgery), within 48 hours after surgery, and 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)

  18. 15-Item Quality of Recovery Questionnaire Score

    Total score on the 2025 Chinese version of the 15-item Quality of Recovery questionnaire at each postoperative assessment. Total scores range from 0 to 150, with higher scores indicating better quality of recovery. Changes between postoperative assessments will be evaluated.

    Time frame: Within 48 hours after surgery and at 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — There is no plan to share de-identified individual participant data with researchers outside the study team.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jan 2029, 26 months later.

Of 53 non-industry interventional studies with no phase under Leiomyoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 43. This study's planned 26 months is below that.

Counting every sponsor, half of 58 studies reached it within 31 months; a quarter within 15 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2026
First posted
Nov 20, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Jan 2029
CompletionEst.
Dec 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950670
Lead sponsor
Hua Li
Responsible party
Hua Li (Chief Physician, Beijing Chao Yang Hospital) — Sponsor-investigator
First posted
Nov 20, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Jan 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Xiali Xiong
Contact
xiongxiali2009@163.com
+86-13520418824

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion